

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Colony Stimulating Factors

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

, , , , , , , , , , , , , , , , , , , ,	, 0,	, , ,	•	
Patient Name:		Prescriber Name:		
HPP Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Line of Business: ☐ Medicaid ☐ CHIP		Specialty Pharmacy (if applicable):		
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:				
Diagnosis Code: Diagnosis:				
HPP's maximum approval time is 12 months but may be less depending on the drug.				
Please attach any pertinent medical history including labs and information for this member that may support approval.				
Please answer the following questions and sign.				
Q1. Is the requested drug prescribed for ether of the following: A) an indication that is included in the U.S. Food and Drug Administration (FDA)-approved package labeling, or B) a medically accepted indication?				
Yes		□No		
Q2. Is the requested drug age-appropriate according to the U.S. Food and Drug Administration (FDA))-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?				
Yes		□ No		
Q3. Is the requested drug prescribed by or in consultation with a hematologist or oncologist?				
☐Yes		□ No		
Q4. Does the patient have a history of a contraindication to the prescribed drug?				
☐ Yes ☐ No				
Q5. Is the requested drug prescribed for primary prophylaxis of chemotherapy-induced febrile neutropenia in a patient with non-myeloid malignancy?				
Yes		☐ No		
Q6. Will the patient be receiving a chemotherapy regimen with an expected incidence of febrile neutropenia greater than 20 percent as defined by the National Comprehensive Cancer Network (NCCN)?				
☐ Yes ☐ No				
Q7. Does the patient have risk factors for de Cancer Network (NCCN)?	eveloping febr	ile neutropenia as defined	by the National Comprehensive	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Colony Stimulating Factors

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:		
☐ Yes	□ No		
Q8. Is the requested drug Neulasta (pegfilgrastim)?			
☐ Yes	□ No		
Q9. Will the patient be receiving the medication during th administration of cytotoxic chemotherapy?	e period beginning 14 days before and ending 24 hours after		
☐ Yes	□ No		
Q10. Is the request for a non-preferred colony stimulating factor product? [Note: See the Preferred Drug List (PDL) for the list of preferred Colony Stimulating Factors at: https://papdl.com/preferred-drug-list]			
☐Yes	□ No		
Q11. Does the patient have a history of therapeutic failure stimulating factors?	e, contraindication, or intolerance of the preferred colony		
☐ Yes	□ No		
Q12. Additional Information:			
Prescriber Signature	 Date		

Updated for 2023